Singapore MOH Launches AIHGle 2.0 — New AI Healthcare Guidelines Put Patients First

The Facts

Singapore's Ministry of Health and Health Sciences Authority jointly published the second edition of the AI in Healthcare Guidelines (AIHGle 2.0) on 10 March 2026, refreshing the original 2021 framework to reflect the significant advancement in clinical AI capabilities over the intervening five years. The updated guidelines provide practical guidance for three distinct stakeholder groups: AI developers (manufacturers), deployers (healthcare organisations), and users (healthcare professionals).

AIHGle 2.0 describes clinical AI tools as "aids that enhance, not replace, professional judgment." This framing acknowledges AI's significant value in augmenting clinical decision-making — flagging suspicious findings in medical imaging, predicting patient deterioration risk, optimising resource allocation — while maintaining that final clinical decisions remain with human healthcare professionals.

AIHGle 2.0 focuses on complex AI systems using machine learning and deep learning algorithms, which carry amplified risks due to their opacity and scalability compared to rule-based clinical software. The guidelines cover two primary clinical use categories: direct clinical decision support (where AI outputs directly influence patient care decisions) and operational applications (where AI optimises non-clinical healthcare processes).

Budget 2026 reinforced these guidelines with financial incentives: the Enterprise Innovation Scheme was expanded to include qualifying AI expenditure generally, not only in healthcare, attracting 400% tax deductions capped at S$50,000 per Year of Assessment for Years of Assessment 2027 and 2028.

Technical Deep-Dive

AIHGle 2.0's accountability framework assigns specific responsibilities to each stakeholder category across the full AI lifecycle — from development through deployment and ongoing monitoring. This triangular accountability model addresses a gap in the original guidelines: when a clinical AI system produces an erroneous output that contributes to patient harm, it was previously unclear which party bore responsibility — the developer who trained the model, the hospital that deployed it, or the clinician who used its output.

Under AIHGle 2.0, each party's responsibilities are explicitly documented. Developers must validate model performance on representative datasets that reflect the local patient population. Deployers must implement ongoing performance monitoring systems that detect model drift — the degradation of model accuracy over time as patient populations, clinical practices, or data collection methods change. Users must maintain sufficient understanding of AI capabilities and limitations to apply appropriate clinical judgement when using AI outputs.

Singapore's HEALIX (Health Empowerment through Advanced Learning and Intelligent eXchange) infrastructure provides the data layer for AI model training and validation. HEALIX enables secure sharing of anonymised clinical, socio-economic, lifestyle, and genomic data across healthcare clusters — addressing the data quality and quantity limitations that have historically constrained clinical AI development in Singapore.